- Home
- KIDS vs ETON Comparison
KIDS vs ETON Comparison
Compare KIDS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | ETON |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.9M | 411.9M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KIDS | ETON |
|---|---|---|
| Price | $17.07 | $18.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $24.56 | ★ $29.67 |
| AVG Volume (30 Days) | 92.1K | ★ 197.8K |
| Earning Date | 03-31-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $98,049,000.00 | $39,011,000.00 |
| Revenue This Year | $16.93 | $107.23 |
| Revenue Next Year | $12.25 | $29.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.95 | 23.29 |
| 52 Week Low | $15.34 | $11.09 |
| 52 Week High | $26.40 | $23.00 |
Technical Indicators
Market Signals| Indicator | KIDS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 74.00 |
| Support Level | $16.58 | $14.49 |
| Resistance Level | $17.48 | $17.63 |
| Average True Range (ATR) | 0.65 | 0.75 |
| MACD | 0.02 | 0.38 |
| Stochastic Oscillator | 52.96 | 97.56 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.